Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
The wave of consolidation so prevalent in advertising is overtaking public relations as well, with Feinstein Kean Partners agreeing to a buyout by Ogilvy Public Relations Worldwide and Cone holding talks with suitors.
Cambridge, Mass.-based Feinstein Kean, which specializes in media and investor relations for pharmaceutical and biotechnology firms, will be acquired by Ogilvy PR in a deal valued at $8-10 million, sources said. Feinstein Kean has 70-80 staffers and has worked for AutoImmune, Biostar, ImmunoGen and Xerox Adaptive Technologies.
The acquisition will likely be announced this week, with Feinstein Kean operating as a unit of Ogilvy PR’s health and medical practice, sources said.
The deal will be financed with cash and publicly traded stock issued by WPP Group, the London-based parent of Ogilvy PR, sources said.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in